Trials / Completed

CompletedNCT00080041

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 20 (planned)

Sponsor: Pharmacyclics LLC. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.

Conditions

Breast Neoplasms
Ovarian Neoplasms
Prostatic Neoplasms
Lung Neoplasms

Interventions

Type	Name	Description
DRUG	Motexafin Gadolinium Injection

Timeline

First posted: 2004-03-23
Last updated: 2007-05-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00080041. Inclusion in this directory is not an endorsement.